The online version of this article (doi:10.1186/s12894-015-0022-9) contains supplementary material, which is available to authorized users.
HRP has received speaker honoraria, as well as honoraria and travel expenses for coloplast educational programs from Eli Lilly. HB, CH, JBA, KHM, JBR and DI are employees of Eli Lilly and Company; HB, KHM and DI also own Lilly stock. NS, BC, DC, and RA have no conflicts of interest to disclose.
HB and CH contributed to drafting the manuscript, HB was also involved in the design of the study. HP, NS, BC, DC, and RA were study investigators, JBR was responsible for clinical trial management. CH was responsible for the statistical analysis. HRP, NS, BC, DC, RA, JBA, KHM, and DI revised the draft manuscript critically. All authors read and approved the final manuscript.
This multicenter, randomized, double-blind, double-dummy, placebo-controlled trial primarily evaluated the efficacy of tadalafil once-daily (OaD) or on-demand (“pro-re-nata”; PRN) treatment, started early post-nsRP. Secondary outcome-measures on quality-of-life (QoL) and treatment satisfaction are reported.
Patients, aged <68 yrs, with adenocarcinoma of the prostate (Gleason ≤ 7, normal preoperative erectile function [EF]) were randomized post-nsRP 1:1:1 to 9-month treatment with tadalafil 5 mg OaD, tadalafil 20 mg PRN, or placebo, followed by 6-week drug-free washout and 3-month open-label tadalafil OaD treatment (OLT). The main outcome measures were Changes in Expanded Prostate Cancer Index Composite (EPIC-26), Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS), and Self-Esteem and Relationship (SEAR) questionnaires (mixed-model-for-repeated-measures, including terms for treatment, visit, treatment-by-visit interaction, age-group, country, baseline-score). LS means with 95% confidence interval (CI) are reported.
423 patients were randomized to 3 treatment-groups: tadalafil OaD (N = 139), PRN (N = 143), or placebo (N = 141). In each group, 57 (41.0%), 58 (40.6%), and 50 (35.5%) patients were aged 61-68 yrs. At the end of double-blind treatment (DBT), patients’ EPIC sexual domain-scores improved significantly with tadalafil OaD versus placebo (treatment effect [95% CI]: 9.6 [3.1,16.0]; p = 0.004); comparisons of PRN versus placebo at end of DBT, and comparisons of tadalafil OaD and PRN versus placebo after OLT were not significant. Only in older patients (61-68 yrs; age-by-treatment p ≤ 0.1), EPIC urinary incontinence domain-scores also improved significantly with tadalafil OaD versus placebo (overall treatment effect across all visits, 8.3 [0.4,16.1]; p = 0.040). Treatment satisfaction increased significantly in both tadalafil groups, EDITS total-scores increased significantly with OaD and PRN versus placebo during DBT (p = 0.005 and p = 0.041, respectively). At the end of OLT, improvement was significant for tadalafil OaD versus placebo only (p = 0.035). No significant differences were observed for SEAR.
These results suggest that chronic dosing of tadalafil improves QoL of patients post-nsRP. The improvement of urinary incontinence in elderly patients randomized to tadalafil OaD may contribute to this effect.
Additional file 1: Table S1. List of Ethical Review Boards. Table S2. Arithmetic mean EPIC domain score changes (patient). Table S3. Arithmetic mean EDITS total scores. Table S4. LSmean changes [95% CI] in SEAR domain scores from baseline. Table S5. Arithmetic mean SEAR scores. Figure S1. Trial design. Figure S2. Patient disposition.12894_2015_22_MOESM1_ESM.docx
Mulhall JP, Donatucci CF, Chiles KA, Büttner H. Management of erectile dysfunction after radical prostatectomy. In: Patel HRH, Mould T, Joseph J, Delaney C, editors. Pelvic cancer surgery: modern breakthroughs and future advances. Verlag London: Springer; 2015. in press.
Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res. 2008;20:479–86. CrossRefPubMed
Sanda MG, Wei JT, Litwin MS. Scoring Instructions for the Expanded Prostate cancer Index Composite Short Form (EPIC-26). [ http://www.med.umich.edu/urology/research/EPIC/EPIC-26-Scoring-1.2007.pdf]
Moncada I, De Bethencourt FR, Lledó-Garcia E, Romero J, Turbi C, Büttner H, et al. Effects of tadalafil once daily or on-demand versus placebo on time to recovery of erectile function in patients after bilateral nerve-sparing radical prostatectomy. World J Urol. 2014, Aug 26. [Epub ahead of print]
Cameron AP, Suskind AM, Neer C, Hussain H, Montgomery J, Latini JM, et al. Functional and anatomical differences between continent and incontinent men post radical prostatectomy on urodynamics and 3T MRI: a pilot study. Neurourol Urodyn. 2014, Apr 21. [Epub ahead of print].
McVary KT, Monnig W, Camps Jr JL, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177:1071–7. CrossRefPubMed
Wittmann DA, West B, Skolarus T, Montie J. Couples’ sexual recovery trajectory after surgery for prostate cancer: change in sexual function, sexual satisfaction and dyadic satisfaction [abstract]. Soc Social Work Res. 2014 Annual Conference, San Antonio, Tx, January 15-19, 2014.
- Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV study
Hitendra R Patel
- BioMed Central
Neu im Fachgebiet Urologie
Meistgelesene Bücher in der Urologie
Mail Icon II